Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.0507
-0.16-75.86%
Last update: May 11, 1:18 PM
Bio-Path Holdings Inc Analyst Ratings
BPTHOTCPK
Bio-Path Holdings Analyst Ratings and Price Targets | OTC:BPTH | Benzinga
Bio-Path Holdings Inc has a consensus price target of $30 based on the ratings of 2 analysts. The high is $40 issued by Roth MKM on March 27, 2024. The low is $20 issued by Roth MKM on July 8, 2024. The 3 most-recent analyst ratings were released by Roth MKM on July 8, 2024, April 18, 2024, and March 27, 2024, respectively. With an average price target of $33.33 between Roth MKM, there's an implied 66433.60% upside for Bio-Path Holdings Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Roth MKM
Roth MKM
1calculated from analyst ratings
Analyst Ratings for Bio-Path Holdings
Loading calendar...
FAQ
What is the target price for Bio-Path Holdings (BPTH) stock?
The latest price target for Bio-Path Holdings (OTCPK:BPTH) was reported by Roth MKM on July 8, 2024. The analyst firm set a price target for $20.00 expecting BPTH to rise to within 12 months (a possible 39347.73% upside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bio-Path Holdings (BPTH)?
The latest analyst rating for Bio-Path Holdings (OTCPK:BPTH) was provided by Roth MKM, and Bio-Path Holdings reiterated their buy rating.
When was the last upgrade for Bio-Path Holdings (BPTH)?
There is no last upgrade for Bio-Path Holdings
When was the last downgrade for Bio-Path Holdings (BPTH)?
There is no last downgrade for Bio-Path Holdings.
When is the next analyst rating going to be posted or updated for Bio-Path Holdings (BPTH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bio-Path Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bio-Path Holdings was filed on July 8, 2024 so you should expect the next rating to be made available sometime around July 8, 2025.
Is the Analyst Rating Bio-Path Holdings (BPTH) correct?
While ratings are subjective and will change, the latest Bio-Path Holdings (BPTH) rating was a reiterated with a price target of $20.00 to $20.00. The current price Bio-Path Holdings (BPTH) is trading at is $0.05, which is out of the analyst’s predicted range.
